Program
Hepatitis B Virus Antisense Oligonucleotide AHB-137
Also written as “AHB-137”, “AHB-137 injection” and “AHB-137 (24 weeks)”.
Its studies are mostly in Hepatitis B, Chronic, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ausper Biopharma | 86 open or running | phase 3since Aug 12, 2025 | Oct 11, 2023 | Dec 12, 2026phase 2 · NCT07137910 |
| AusperBio Therapeutics | 32 open or running | phase 2since Jan 19, 2026 | Jan 20, 2023 | May 11, 2027phase 2 · NCT07654283 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 20, 2023First study: phase 1 study in Hepatitis B, ChronicNew to AusperBio TherapeuticsAusperBio Therapeutics · NCT05717686 · 64 enrolled · United States, Hong Kong, New Zealand and more
- Oct 11, 2023Ausper Biopharma’s first study: phase 2 study in Hepatitis B, ChronicNew to Ausper BiopharmaAusper Biopharma · NCT06115993 · 129 enrolled · China
- Aug 5, 2024Phase 2 study in Hepatitis B, ChronicAusper Biopharma · NCT06550128 · 86 enrolled · China
- May 16, 2025Phase 2 study in Hepatitis B, ChronicAusper Biopharma · NCT06993480 · 20 enrolled · China
- Jun 25, 2025Phase 2 study in Hepatitis B, ChronicAusper Biopharma · NCT07069569 · 200 planned · China
- Aug 12, 2025Phase 3 study in Hepatitis B, ChronicAusper Biopharma · NCT07246889 · 577 enrolled · China
- Aug 15, 2025Phase 2 study in Hepatitis B, ChronicAusper Biopharma · NCT07137910 · 200 planned · China
- Jan 19, 2026Phase 2 study in Hepatitis B, ChronicPhase 2 reachedAusperBio Therapeutics · NCT07370207 · 84 planned · Australia, China, Japan and more
- May 14, 2026Phase 1 study in Hepatitis B, ChronicAusper Biopharma · NCT07600788 · 32 planned · China
- May 28, 2026Phase 2 study in Hepatitis B, ChronicAusperBio Therapeutics · NCT07654283 · 70 planned · United States, Canada, France and more
- May 28, 2026Phase 2 study in Hepatitis B, ChronicAusper Biopharma · NCT07635186 · 320 planned · China
Ahead
- Dec 12, 2026Primary completion: phase 2 study in Hepatitis B, ChronicAusper Biopharma · NCT07137910
- Dec 18, 2026Primary completion: phase 3 study in Hepatitis B, ChronicAusper Biopharma · NCT07246889
- May 11, 2027Primary completion: phase 2 study in Hepatitis B, ChronicAusperBio Therapeutics · NCT07654283
- Jun 20, 2027Primary completion: phase 2 study in Hepatitis B, ChronicAusper Biopharma · NCT07635186
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07654283Hepatitis B, Chronic · United States, Canada, France and more | 2 | Recruiting | AusperBio Therapeutics | May 11, 2027 | 70 |
| NCT07635186Hepatitis B, Chronic · China | 2 | Recruiting | Ausper Biopharma | Jun 20, 2027 | 320 |
| NCT07600788Hepatitis B, Chronic · China | 1 | Recruiting | Ausper Biopharma | May 15, 2028 | 32 |
| NCT07370207Hepatitis B, Chronic · Australia, China, Japan and more | 2 | Recruiting | AusperBio Therapeutics | Dec 31, 2028 | 84 |
| NCT07137910Hepatitis B, Chronic · China | 2 | Recruiting | Ausper Biopharma | Dec 12, 2026 | 200 |
| NCT07246889Hepatitis B, Chronic · China | 3 | Active, not recruiting | Ausper Biopharma | Dec 18, 2026 | 577 |
| NCT07069569Hepatitis B, Chronic · China | 2 | Recruiting | Ausper Biopharma | Jul 15, 2027 | 200 |
| NCT06993480Hepatitis B, Chronic · China | 2 | Active, not recruiting | Ausper Biopharma | Jul 27, 2027 | 20 |
| NCT06550128Hepatitis B, Chronic · China | 2 | Completed | Ausper Biopharma | May 26, 2025 | 86 |
| NCT06115993Hepatitis B, Chronic · China | 2 | Completed | Ausper Biopharma | Dec 3, 2024 | 129 |
| NCT05717686Hepatitis B, Chronic · United States, Hong Kong, New Zealand and more | 1 | Completed | AusperBio Therapeutics | Jan 7, 2025 | 64 |
How it is read
Names in the registry
- “AHB-137”, 7 entries
- “AHB-137 injection”, 3 entries
- “AHB-137 (24 weeks)”, 1 entry
- “AHB-137 (16 weeks)”, 1 entry
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 11 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.